The deal, announced today, includes RTI Surgical acquiring Exactech’s FDA-cleared Optecure demineralized bone matrix, used as a bone graft extender in the spine, pelvis, and extremities. RTI Surgical officials think Optecure will complement their portfolio of bone graft substitutes. RTI Surgical offers a portfolio of tissue-based, synthetic and metal implants to OEM customers.
The financial terms of the deal were not disclosed.
“Biologic materials that support joint replacement surgery are an important facet of Exactech’s business,” Exactech CEO Darin Johnson said in a news release.
“This collaboration with RTI allows each company to focus on our unique strengths,” Johnson said. “RTI has specialized expertise in the procurement, processing and manufacturing of human-derived tissue-based implants, and Exactech markets and distributes the clinical solutions to help surgeons treat patients.”
RTI Surgical CEO seeks to become the market leading private-label implant supplier to OEMs, according to CEO Olivier Visa. Growing our partnership with Exactech and developing Optecure enables us to achieve our vision of enhancing the gifts of life, and we thank the Exactech team for this partnership.”
Optecure is RTI Surgical’s first product acquisition since private equity firm Montagu acquired the RTI Surgical OEM business in 2020.